$482.00
+0.31%
N/A+$1.50
Healthcare
Biotechnology
NASDAQ
Active Trading
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic ...
Financial highlights
Latest / TTM · 6 periods
Snapshot
Latest / TTM: 2026-07-22
Gross Margin
—
Net Margin
—
P/E Ratio
—
Debt / Equity
—
Profitability
Profitability table
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Gross MarginGross profit as a percentage of revenue. | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% | — |
| Operating MarginOperating income as a percentage of revenue. | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% | — |
| Net MarginNet income as a percentage of revenue. | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% | — |
| EBITDA MarginEBITDA divided by revenue. | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% | — |
| Pre-tax MarginPre-tax profit as a percentage of revenue. | 36.0% | 47.4% | 44.4% | 2.3% | 38.5% | — |
Liquidity & leverage
Liquidity & leverage table
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Current RatioCurrent assets divided by current liabilities. | 4.46 | 4.83 | 3.99 | 2.69 | 2.90 | — |
| Quick RatioLiquid assets divided by current liabilities. | 4.30 | 4.66 | 3.78 | 2.35 | 2.46 | — |
| Cash RatioCash and equivalents divided by current liabilities. | 3.17 | 3.83 | 2.92 | 1.28 | 1.32 | — |
| Debt / AssetsDebt as a share of total assets. | 7.2% | 5.0% | 3.6% | 7.8% | 14.9% | — |
| Debt / EquityDebt compared with shareholder equity. | 0.10 | 0.06 | 0.05 | 0.11 | 0.21 | — |
Operating efficiency
Operating efficiency table
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Receivables TurnoverHow often receivables are collected in a year. | 6.66x | 6.19x | 6.31x | 6.85x | 5.88x | — |
| Inventory TurnoverHow often inventory is sold in a year. | 2.56x | 2.35x | 1.71x | 1.27x | 1.07x | — |
| Payables TurnoverHow often payables are paid in a year. | 4.64x | 3.55x | 3.46x | 3.71x | 3.91x | — |
| Asset TurnoverRevenue generated per dollar of assets. | 0.56x | 0.49x | 0.43x | 0.49x | 0.46x | — |
| Working Capital TurnoverRevenue generated per dollar of working capital. | 1.11x | 1.00x | 0.94x | 1.33x | 1.81x | — |
Valuation ratios
Valuation ratios table
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| P/E RatioPrice paid for each dollar of earnings. | 24.16x | 22.27x | 28.96x | -193.61x | 29.32x | — |
| P/B RatioPrice paid for each dollar of book value. | 5.60x | 5.32x | 5.96x | 6.32x | 6.21x | — |
| P/S RatioPrice paid for each dollar of sales. | 7.47x | 8.28x | 10.62x | 9.41x | 9.60x | — |
| P/FCF RatioPrice paid for each dollar of free cash flow. | 23.50x | 18.84x | 31.98x | -131.21x | 36.30x | — |
| Dividend YieldAnnual dividend divided by current share price. | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |